FRIES, WALTER
 Distribuzione geografica
Continente #
NA - Nord America 113
AS - Asia 61
EU - Europa 38
SA - Sud America 17
Continente sconosciuto - Info sul continente non disponibili 9
AF - Africa 2
Totale 240
Nazione #
US - Stati Uniti d'America 110
SG - Singapore 28
IT - Italia 25
BR - Brasile 15
CN - Cina 15
VN - Vietnam 7
IN - India 5
SE - Svezia 4
CA - Canada 2
DE - Germania 2
GB - Regno Unito 2
AO - Angola 1
AR - Argentina 1
AT - Austria 1
AZ - Azerbaigian 1
CL - Cile 1
DZ - Algeria 1
FR - Francia 1
HK - Hong Kong 1
ID - Indonesia 1
IR - Iran 1
MD - Moldavia 1
MX - Messico 1
PT - Portogallo 1
RS - Serbia 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 231
Città #
San Jose 19
Singapore 11
Ashburn 10
Catanzaro 8
Santa Clara 6
Bengaluru 5
Collegeville 5
Council Bluffs 5
Hefei 5
Milan 5
Beijing 4
Chandler 4
Ho Chi Minh City 4
Lawrence 4
Los Angeles 4
Princeton 4
São Paulo 3
Boardman 2
Dallas 2
Des Moines 2
New York 2
Orem 2
Redwood City 2
Wilmington 2
Almirante Tamandaré 1
Altadena 1
Ankara 1
Baku 1
Belgrade 1
Biên Hòa 1
Cachoeiras de Macacu 1
Cacuaco 1
Caldeirão Grande do Piauí 1
Cantemir 1
Carencro 1
Cincinnati 1
Colombo 1
Da Nang 1
Duque de Caxias 1
Hanoi 1
Henderson 1
Hong Kong 1
Houston 1
Indaiatuba 1
Juiz de Fora 1
Lanús 1
Limeira 1
London 1
Loves Park 1
Lugo 1
Messina 1
Mexico City 1
Mohammadia 1
Munich 1
Nuremberg 1
Ottawa 1
Quilicura 1
Rockville 1
Rome 1
San Mateo 1
Stockholm 1
São Bento 1
Tabriz 1
Tashkent 1
Taubaté 1
Viamão 1
Totale 162
Nome #
Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy 73
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study 46
Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease 39
Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab 35
Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis 34
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC) 8
Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study 5
Totale 240
Categoria #
all - tutte 2.467
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.467


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228 0 0 0 2 1 1 0 2 0 0 2 0
2022/202315 8 3 0 1 0 0 0 0 0 0 2 1
2023/202417 5 4 1 3 0 2 0 0 0 0 1 1
2024/202529 6 0 0 2 2 7 1 0 0 0 4 7
2025/2026128 14 12 14 16 13 3 13 14 18 5 4 2
2026/202717 2 15 0 0 0 0 0 0 0 0 0 0
Totale 240